SENATE JOINT RESOLUTION 8

J1 7lr2896

By: Senators Klausmeier, Astle, Brochin, Dyson, and Middleton

Introduced and read first time: February 22, 2007

Assigned to: Rules

2

12

13

14

18

19 20

21

2223

SENATE JOINT RESOLUTION

1 A Senate Joint Resolution concerning

Federal Legislation Regarding Medicare Part D

3 FOR the purpose of urging the Maryland Congressional Delegation and the President of the United States to enact legislation to simplify premiums, deductibles, 4 5 copayments, and formularies in plans made available to Medicare beneficiaries, 6 to eliminate the coverage gap in the Medicare Part D prescription drug benefit, 7 and to repeal the parts of the Medicare Prescription Drug, Improvement, and 8 Modernization Act of 2003 that prevent the Secretary of Health and Human 9 Services from negotiating lower drug prices with pharmaceutical companies on 10 behalf of Medicare beneficiaries; and generally relating to federal legislation regarding Medicare Part D. 11

WHEREAS, The United States Congress passed and the President of the United States signed into law the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA); and

WHEREAS, The MMA added a voluntary prescription drug benefit under Medicare Part D, beginning January 1, 2006, which is offered to Medicare beneficiaries; and

WHEREAS, There has been widespread confusion among Medicare beneficiaries trying to choose from dozens of Medicare Part D plans with different premiums, deductibles, copayments, and formularies; and

WHEREAS, To receive Medicare Part D benefits, a participating beneficiary with an income greater than 150% of the federal poverty level must enroll in a private prescription drug plan and pay a monthly premium, deductible, and copayment



toward the cost of covered prescription drugs until the beneficiary's total annual prescription drug costs reach \$2,250; and

WHEREAS, At the point at which a beneficiary's total annual drug costs reach \$2,250, the MMA creates a \$2,850 gap in coverage, which is known as the "donut hole"; and

WHEREAS, It is not until drug costs reach \$5,100 in a year, the catastrophic threshold, that the participating Medicare beneficiary would again receive prescription drug coverage, this time paying a 5% copayment for covered prescription drugs; and

WHEREAS, The \$2,850 "donut hole" means that many Medicare beneficiaries who reach \$2,250 in prescription drug costs will continue to pay monthly premiums, but will not receive coverage for their prescription drugs, unless and until their total annual prescription drug costs reach the \$5,100 catastrophic threshold; and

WHEREAS, Many participating beneficiaries who reach the "donut hole" will not reach the catastrophic threshold before the end of the year; and

WHEREAS, The MMA should be revised to ensure that Medicare beneficiaries who enroll in prescription drug plans and pay their premiums, deductibles, and copayments continue to receive coverage for their covered prescription drugs, without a "donut hole" that contravenes the laudable goal of the MMA to provide prescription drugs to Medicare beneficiaries; and

WHEREAS, Those Medicare beneficiaries who took the initiative and acted responsibly, by purchasing prescription drug coverage as insurance against future, unknown prescription drug needs or to help defray the prescription drug costs of managing their current medical conditions, should not lose sorely needed prescription drug coverage because their annual prescription drug costs placed them in the "donut hole"; and

WHEREAS, The MMA prohibits the Secretary of Health and Human Services from negotiating lower drug prices with pharmaceutical companies on behalf of Medicare beneficiaries; and

WHEREAS, The Center for Economic and Policy Research estimates that Medicare price negotiation could reduce prescription drug prices by 50%, enough to close the "donut hole", reduce premiums and copayments, and cut overall drug spending; now, therefore, be it

RESOLVED BY THE GENERAL ASSEMBLY OF MARYLAND, That the General Assembly respectfully urges the Maryland Congressional Delegation and all members of Congress to pass, and the President of the United States to sign into law, legislation that would revise the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to simplify premiums, deductibles, copayments, and formularies in plans made available to Medicare beneficiaries; to ensure that Medicare beneficiaries who enroll in prescription drug plans and pay their premiums, deductibles, and copayments continue to receive coverage for their covered prescription drugs without a gap in coverage, or "donut hole", after annual prescription drug costs reach certain limits; and to repeal the prohibition on negotiating drug prices with pharmaceutical companies on behalf of Medicare beneficiaries; and be it further

RESOLVED, That a copy of this Resolution be forwarded by the Department of Legislative Services to President George W. Bush, The White House, Washington, D.C. 20500; and to the Maryland Congressional Delegation: Senators Barbara A. Mikulski, and Benjamin L. Cardin, Senate Office Building, Washington, D.C. 20510; and Representatives Wayne T. Gilchrest, C. A. Dutch Ruppersberger III, John P. Sarbanes, Albert R. Wynn, Steny Hamilton Hoyer, Roscoe G. Bartlett, Elijah E. Cummings, and Christopher Van Hollen, Jr., House Office Building, Washington, D.C. 20515; and be it further

RESOLVED, That that a copy of this Resolution be forwarded by the Department of Legislative Services to the Honorable Martin O'Malley, Governor of Maryland; the Honorable Thomas V. Mike Miller, Jr., President of the Senate of Maryland; and the Honorable Michael E. Busch, Speaker of the House of Delegates.